Drug profile · INN
oxybutynin
DITROPAN
oxybutynin (DITROPAN) is a muscarinic acetylcholine receptor m2 antagonist. Associated with Sanofi-aventis Healthcare Pty Ltd. Route of administration: transdermal. Current US regulatory status: approved.
Drug details — oxybutynin
- US status
- approved
- Class
- Genito-urinary system and sex hormones (G04)
- Route
- TRANSDERMAL
- Patents
- 0
- Programs
- 4
- Data quality
- 0.89
Quick answer
oxybutynin (DITROPAN) is a muscarinic acetylcholine receptor m2 antagonist. Associated with Sanofi-aventis Healthcare Pty Ltd. Route of administration: transdermal. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscarinic acetylcholine receptor M2 antagonist
Primary target: Muscarinic acetylcholine receptor M2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is oxybutynin?
oxybutynin (DITROPAN) is a muscarinic acetylcholine receptor m2 antagonist. Associated with Sanofi-aventis Healthcare Pty Ltd. Route of administration: transdermal. Current US regulatory status: approved.
What is the brand name for oxybutynin?
DITROPAN is a marketed brand name for oxybutynin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of oxybutynin?
oxybutynin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.